title: A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication.
abstract: Pharmacologic therapy for intermittent claudication in patients with peripheral artery disease (PAD) is limited. We aimed to determine the durability of cilostazol treatment response over time, treatment effects in various subpopulations, and long-term safety. This analysis pooled original data from nine randomized, controlled trials evaluating cilostazol in intermittent claudication, including 1258 subjects treated with cilostazol 100 mg bid. Analysis of covariance was used to compare differences in walking distance, and a pooled random-effects weighted mean difference in maximal walking distance (MWD) was determined. Temporal effects were analyzed by compiling data at 4-week intervals in studies of 24 weeks in duration. Cilostazol was associated with a 50.7% improvement from baseline in MWD compared with placebo (24.3%), with an absolute improvement of 42.1 meters greater than the improvement with placebo (p < 0.001) over a mean follow-up period of 20.4 weeks. Continued increases were demonstrated over the 24-week treatment period. These benefits were seen in all subgroups, after stratifying by age, sex, smoking status, duration of PAD, diabetes, hypertension, prior myocardial infarction, or beta-blocker use. Cilostazol did not increase the risk of all-cause mortality (RR 0.95 [0.68-1.35]). In conclusion, treatment with cilostazol achieves benefits in walking distance that are sustained at 24 weeks and observed irrespective of baseline clinical characteristics. Cilostazol demonstrated no increased risk of all-cause mortality.
authors.affiliation: Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. rpande@partners.org
authors.forename: Reena L
authors.initials: RL
authors.lastname: Pande
authors.forename: William R
authors.initials: WR
authors.lastname: Hiatt
authors.forename: Peter
authors.initials: P
authors.lastname: Zhang
authors.forename: Norbert
authors.initials: N
authors.lastname: Hittel
authors.forename: Mark A
authors.initials: MA
authors.lastname: Creager
mesh_terms: D000077407:Cilostazol; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy* / Q000401:mortality; D011237:Predictive Value of Tests; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D012307:Risk Factors; D013777:Tetrazoles / Q000008:administration & dosage* / Q000009:adverse effects; D013812:Therapeutics; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D013777:Tetrazoles; D014665:Vasodilator Agents; D000077407:Cilostazol
references.citation: Am J Med. 2000 Nov;109(7):523-30
references.pmid: 11063952
references.citation: Vasc Med. 1999;4(4):239-46
references.pmid: 10613628
references.citation: Circulation. 1989 Nov;80(5 Pt 2):III59-72
references.pmid: 2680161
references.citation: Thromb Res. 1990 Feb 15;57(4):617-23
references.pmid: 2158154
references.citation: J Atheroscler Thromb. 2003;10(2):93-8
references.pmid: 12740483
references.citation: N Engl J Med. 1991 Nov 21;325(21):1468-75
references.pmid: 1944425
references.citation: Circulation. 1998 Aug 18;98(7):678-86
references.pmid: 9715861
references.citation: Arterioscler Thromb Vasc Biol. 1998 Dec;18(12):1942-7
references.pmid: 9848888
references.citation: Pharmacology. 1988;36(5):313-20
references.pmid: 2841693
references.citation: Med Care. 1992 Jun;30(6):473-83
references.pmid: 1593914
references.citation: Vasc Endovascular Surg. 2002 Mar-Apr;36(2):83-91
references.pmid: 11951094
references.citation: Clin Pharmacol Ther. 2002 Apr;71(4):246-52
references.pmid: 11956507
references.citation: Am J Cardiol. 2002 Dec 15;90(12):1314-9
references.pmid: 12480040
references.citation: J Vasc Surg. 1998 Dec;28(6):1072-81
references.pmid: 9845659
references.citation: Br J Surg. 1997 Aug;84(8):1107-9
references.pmid: 9278653
references.citation: Med Sci Sports Exerc. 1992 Feb;24(2):163-70
references.pmid: 1549004
references.citation: Cochrane Database Syst Rev. 2008 Jan 23;(1):CD003748
references.pmid: 18254032
references.citation: J Vasc Surg. 1998 Feb;27(2):267-74; discussion 274-5
references.pmid: 9510281
references.citation: Arch Intern Med. 1999 Sep 27;159(17):2041-50
references.pmid: 10510990
references.citation: Angiology. 1993 Jan;44(1):1-10
references.pmid: 8424578
references.citation: J Vasc Surg. 2008 Feb;47(2):330-336
references.pmid: 18155871
references.citation: J Am Geriatr Soc. 2002 Dec;50(12):1939-46
references.pmid: 12473004
references.citation: JAMA. 1995 Sep 27;274(12):975-80
references.pmid: 7674529